Ainos (AIMD) 10-K 30 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 30, 2020
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	0001014763
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		40,516,351
Entity Public Float	$ 9,138,942
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 409,039	$ 1,276,654
Inventory	4,131
Prepaid expense and other current assets	32,124	26,580
Total current assets	445,294	1,303,234
Patents, net	146,263	146,456
Property and equipment, net	5,069	14,010
Total assets	596,626	1,463,700
Liabilities and Stockholders’ Equity (Deficit)
Accounts payable and accrued expenses	208,727	115,313
Advances from investors	100,000	104,952
Convertible notes payable	444,581	513,356
Total current liabilities	753,308	733,621
Total liabilities	753,308	733,621
Commitments and contingencies
Stockholders’ equity (deficit)
Preferred stock, $0.01 par value: Authorized shares – 10,000,000, Issued and outstanding shares – 0 at December 31, 2019 and December 31, 2018, respectively
Common stock, $0.01 par value: Authorized shares – 100,000,000, Issued and outstanding shares –40,516,351 and 39,117,524 at December 31, 2019 and 2018, respectively	405,164	391,175
Additional paid-in capital	4,207,786	3,527,238
Accumulated deficit	(4,769,632)	(3,188,334)
Total stockholders’ equity (deficit)	(156,682)	730,079
Total liabilities and stockholders’ equity (deficit)	$ 596,626	$ 1,463,700

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	40,516,351	39,117,524
Common stock, shares outstanding (in shares)	40,516,351	39,117,524

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 11,731	$ 77,724
Cost of revenues	(8,772)	(64,877)
Gross margin	2,959	12,847
Operating expenses:
Research and development expenses	52,510	32,591
Selling, general and administrative expenses	1,530,862	1,314,932
Total operating expenses	1,583,372	1,347,523
Operating loss	(1,580,413)	(1,334,676)
Other income (expense):
Interest expense, net	(885)	(3,963)
Net loss	$ (1,581,298)	$ (1,338,639)
Basic and diluted net loss per average share available to common shareholders (in dollars per share)	$ (0.04)	$ (0.04)
Weighted average common shares outstanding – basic and diluted (in shares)	39,896,388	35,643,804

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017		23,156,563
Balance at Dec. 31, 2017		$ 231,565	$ 2,123,205	$ (1,883,975)	$ 470,795
Reversal of dividends on preferred stock				34,280	34,280
Issuance of stock for compensation (in shares)		451,480
Issuance of stock for compensation		$ 4,515	111,735		116,250
Issuance of stock for subscription (in shares)		8,579,061
Issuance of stock for subscription		$ 85,791	(85,791)
Issuance of common stock for cash (in shares)		5,440,973
Issuance of common stock for cash		$ 54,410	1,067,875		1,122,285
Issuance of stock for debt (in shares)		950,000
Issuance of stock for debt		$ 9,500	168,625		178,125
Acquisition of assets of ACTS (in shares)		539,447
Acquisition of assets of ACTS		$ 5,394	13,458		18,852
Warrant expense			27,765		27,765
Option expense			100,366		100,366
Net loss for the year ended December 31				(1,338,639)	(1,338,639)
Balance (in shares) at Dec. 31, 2018		39,117,524
Balance at Dec. 31, 2018		$ 391,175	3,527,238	(3,188,334)	730,079
Reversal of dividends on preferred stock
Issuance of stock for compensation (in shares)		231,675
Issuance of stock for compensation		$ 2,317	67,183		69,500
Issuance of stock for subscription
Issuance of common stock for cash (in shares)		615,000
Issuance of common stock for cash		$ 6,150	123,850		130,000
Issuance of stock for debt (in shares)		552,152
Issuance of stock for debt		$ 5,522	94,478		100,000
Warrant expense			37,984		37,984
Option expense			357,053		357,053
Net loss for the year ended December 31				(1,581,298)	(1,581,298)
Balance (in shares) at Dec. 31, 2019		40,516,351
Balance at Dec. 31, 2019		$ 405,164	$ 4,207,786	$ (4,769,632)	$ (156,682)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from Operating Activities
Net loss	$ (1,581,298)	$ (1,338,639)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	22,241	56,194
Warrant expense	37,984	27,765
Option expense	357,053	100,366
Amortization of debt discount
Changes in operating assets and liabilities:
Inventory	(4,131)	22,666
Prepaid expense and other current assets	(5,544)	67,400
Accounts payable and accrued expenses	261,674	54,844
Accrued interest – related party	2,545	206
Customer deposits
Net cash used in operating activities	(909,476)	(1,009,198)
Cash flows from Investing Activities
Investment in patents	(11,469)	(2,369)
Capital expenditures	(1,638)	(4,908)
Net cash used in investing activities	(13,107)	(7,277)
Cash flows from Financing Activities
Cash received from stock subscription
Proceeds from private placement offering, net	125,048	401,250
Advances from investors		48,729
Proceeds from convertible note payable – related party
Repayment on convertible note payable – related party	(70,080)	(195,000)
Net cash provided by financing activities	54,968	254,979
Net change in cash	(867,615)	(761,496)
Cash and cash equivalents at beginning of period	1,276,654	2,038,150
Cash and cash equivalents at end of period	409,039	1,276,654
Supplemental Cash Flow Information
Cash paid for interest	903	3,818
Cash paid for income taxes
Non-Cash Transactions
Stock issued for accrued liabilities	69,500	116,250
Stock issued for subscription		85,791
Conversion of debt to common stock	100,000	178,125
Reversal of accrued dividends		34,280
Stock issued for advances from investors	$ 100,635	$ 721,035

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Summary of Significant Accounting Policies Organization and Business Amarillo Biosciences, Inc. (the "Company" or "ABI"), is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. ABI is a Texas corporation which was formed in 1984. ABI primarily operates through three 1 2 Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, not ● Level 3, no one Our Level 1 Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three Revenue Recognition In May 2014, 2014 09, August 2015, March 2016, April 2016, May 2016, December 2016 2015 14, 2016 08, 2016 10, 2016 12 2016 20, five two On January 1, 2018, 606 no no Results for reporting periods beginning after January 1, 2018 606, not 605, The Company's primary source of revenue is the sale of products within three The Medical division periodically provides medical equipment to metabolism treatment centers in Taiwan and Hong Kong. Additionally, this division provides TissueAid TM The Pharmaceutical Division is currently seeking to leverage the Company's intellectual property and core technology, low-dose oral interferon, to expand treatment of the aforementioned neoplastic, viral, and fibrotic diseases as well as other potential indications. Revenue recognized during the year ended December 31, 2019 2018 Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not one no no December 31, 2019 2018. $7,320 2018. Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven Patents and Patent Expenditures ABI holds patent license agreements and maintains patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 No December 31, 2019. December 31, 2018, $16,000 Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not Research and Development Research and development costs are expensed as incurred. During the years ended December 31, 2019, December 31, 2018, $52,510 $32,591, not Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and Diluted Net Income ( Loss ) Per Share As of December 31, 2019, 3,099,867 not Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single U.S. financial institution which, from time to time, could exceed the federally insured limit of $250,000. December 31, 2019, $69,634.No Recent Accounting Pronouncements In February 2016, No. 2016 02 2016 02 842 2016 02 12 2016 02 2016 02 2016 02 December 15, 2018, 2016 02 January 1, 2019. no In June 2018, 2018 07, 718 2018 07” 2018 07 718 2018 07 718 not 1 2 606 2018 07 December 15, 2018, 2018 07 January 1, 2019. 2018 07 not Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not not

Note 2 - Property, Equipment an

Note 2 - Property, Equipment and Software, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	2. Property, equipment and software are stated at cost less accumulated depreciation and consist of the following at December 31, 2019 2018: 2019 2018 Furniture and equipment $ 94,625 $ 92,988 Automobiles 4,912 4,911 Software 8,012 8,012 107,549 105,911 Less: accumulated depreciation (102,480 ) (91,901 ) Property, equipment and software, net $ 5,069 $ 14,010 Depreciation expense amounted to $10,579 December 31, 2019 $17,895 December 31, 2018

Note 3 - Patents, Net

Note 3 - Patents, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	3. Patents are stated at cost less accumulated amortization and consist of the following at December 31, 2019 2018: 2019 2018 Patents $ 198,655 $ 228,669 Less: accumulated amortization (52,392 ) (82,213 ) Patents, net $ 146,263 $ 146,456 During the year ended December 31, 2018, $112,022 $96,055 $15,967 Amortization expense amounted to $11,662 December 31, 2019 $38,296 December 31, 2018, Estimated future amortization expense is as follows: 2019 11,957 2020 10,655 2021 10,251 2022 10,251 2023 10,251 Thereafter 92,898 Total expense $ 146,263

Note 4 - Convertible Notes Paya

Note 4 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. As of December 31, 2019 2018, Conversion rate Interest rate December 31 2019 December 31, 2018 Note 1 – Chen $0.1680 0.75% $ 114,026 $ 144,426 Note 2 - Chen $0.1875 0.65% 262,500 262,500 Note 3 - Chen $0.1875 0.64% - 106,430 Note 3.19 – Chen++ $0.2500 1.85% 39,620 - Note 4.19 - Chen $0.2500 1.61% 12,435 - Note 5.19 – i2China $0.2500 1.85% 16,000 - $ 444,581 $ 513,356 The notes are unsecured and are due on demand. All shares issued on conversion are to be restricted subject to Rule 144 1933. may 6.

Note 5 - ACTS Global

Note 5 - ACTS Global	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	5. ACTS Global On May 23, 2016, may may one 1% Since the inception of the Agency Agreement in 2016, no January 1, 2018 On June 18, 2018, July 1, 2018, 539,447 July 12, 2018, 539,447 Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6 . Related Party Transactions As discussed in Note 4, December 31, 2019 2018, $428,581 $513,356, 2019 2018 $4,094 $4,024. On July 12, 2018, 125,852

Note 7 - Common Stock

Note 7 - Common Stock	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7 . Common Stock The shareholders have authorized 100,000,000 December 31, 2019, 48,673,437 40,516,351 2,350,949 400,000 two 238,997 one 6,309 51,214 4,657,000 3 452,617 During 2018, 3,740,973 $721,035 2017 2017 During 2018, 1,700,000 $401,250. During 2018, 451,480 $116,250. On April 1, 2018, $178,125 950,000 $.1875 Effective July 1, 2018, 539,447 On February 19, 2019, 200,000 $0.25 $50,000 2016 3 On February 26, 2019, 100,000 12,000 fourth 2018 $28,000. March 27, 2018, $0.25 On February 26, 2019, 24,000 $0.25 fourth 2018. $6,000. 3 4,657,000 1,217,375 December 31, 2019. On March 26, 2019, 115,000 $0.25 $28,750. On April 26, 2019, 67,377 $0.3711 $25,000 first 2019. April 26, 2019, 8,085 $.3711 $3,000 first 2019 4,043 $0.3711 $1,500 first 2019. 16,170 $0.3711 first $6,000. On July 10, 2019, $68,930 June 30, 2016 $670 371,200 $0.1875 July 10, 2019, $30,400 January 30, 2016 180,952 $0.1681. On December 1, 2019, 300,000 $0.1875 $56,250 2016 2 November 23, 2017, not 2019. Accrual for 2019 2020. Beneficiary Accrued Compensation Quarter 2 Accrued Compensation Quarter 3 Accrued Compensation Quarter 4 Total Compensation Total Shares 1 Dr. Stephen T. Chen $ 25,000 $ 25,000 $ 25,000 $ 75,000 213,390 Bernard Cohen $ 3,000 $ 3,000 $ 3,000 $ 9,000 25,607 Dr. Celee Spidel $ 1,500 $ 750 - $ 2,250 6,309 i2China Mgt., LLC $ 6,000 $ 6,000 $ 6,000 $ 18,000 51,214 Total $ 35,500 $ 34,750 $ 34,000 $ 104,250 296,520 Price Per Share $ 0.3499 $ 0.4183 $ 0.3043 1 2019 on February 15, 2020 for 2019 On September 15, 2019, 2019 1 24,000,000 not $6,000,000. December 17, 2019. On December 18, 2019, 2019 2 12,000,000 $0.25 $3,000,000. one On December 31, 2019, $100,000 400,000 $0.25 2019 2 February 15, 2020. The Company did not 2019 no Amarillo Biosciences, Inc. uses the services of American Stock Transfer and Trust Company as the Company’s transfer agent.

Note 8 - Preferred Stock

Note 8 - Preferred Stock	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	8 . Preferred Stock The shareholders have authorized 10,000,000 No December 31, 2019 2018 none

Note 9 - Stock Option and Stock

Note 9 - Stock Option and Stock Plans	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9 . Stock Option and Stock Plans On September 26, 2018, 2018 “2018 2018 2018 2018 2018 one 2018 may 2018 six million 6,000,000 The option price per share of Common Stock deliverable upon the exercise of an Incentive Stock Option is 100% $0.38 ten 10 20% five 5 one 1 ten 10% 424 110% $0.418; five 5 ten 10 five 5 four 4 Since approval of the “2018 September 26, 2018 no not “2018 September 26, 2019. On September 26, 2018, 2018 “2018 2018 2018 may 2018 twenty million 20,000,000 $0.38 ten 10 five 5 20% one 1 no ten 10% Equity Compensation Plan Information: Stock Plans 1 Issue Date Range Total Shares Authorized Shares Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580 Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan 2 9/26/18 – 9/26/28 6,000,000 850,000 5,150,000 Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 9/26/18 – 9/26/28 20,000,000 3,807,000 16,193,000 1 2 September 26, 2019, 2018 not Whether qualified or nonqualified, when options are exercised, the ABI Common Stock shares will be issued pursuant to Rule 144A six A summary of option activity for the years ended December 31, 2018 December 31, 2019 Date Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance December 31, 2017 - - - - Granted 4,945,000 $ 0.38 - - Exercised - - - - Expired or Forfeited - - - - Balance December 31, 2018 4,945,000 $ 0.38 9 - Granted - - - - Exercised - - - - Forfeited 288,000 $ 0.38 - - Balance December 31, 2019 4,657,000 $ .038 8 - Total vested December 31, 2019 1,217,375 $ .038 8 - * There is one 10% 500,000 $0.418 5 4 25% The Company used the Black-Scholes option pricing model to value the option awards with the following assumptions applied: ( 1 276%; 2 5 10 5 3 2.96% As of December 31, 2019, $1,308,932 3.75 Directors, officers, employees and consultants did not 2019 2018.

Note 10 - Warrants

Note 10 - Warrants	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Warrant Disclosure [Text Block]	10. On April 15, 2018, 452,617 $0.27 April 14, 2020. $75,967 twenty-four 1 207%; 2 2 3 2.39%. No 2019 2018.

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income tax expense (benefit) attributable to income from continuing operations differed from the amounts computed by applying the U.S. Federal income tax of 21% December 31, 2019 December 31, 2018 Provision (benefit) at statutory rate $ (332,000 ) $ (281,000 ) Permanent differences 85,000 30,000 Change in valuation allowance 247,000 251,000 $ - $ - The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2019 2018, December 31, 2019 December 31, 2018 Deferred tax assets: Net operating loss carryforward $ 5,239,000 $ 4,992,000 Deferred tax assets 5,239,000 4,992,000 Deferred tax liabilities: - - Net deferred tax assets 5,239,000 4,992,000 Valuation allowance (5,239,000 ) (4,992,000 ) $ - $ - At December 31, 2019, $24,948,000 2019 2037. may not 4 not believe the reorganization has or will impair any tax attributes; however, obtaining value from the tax attributes is a function of the Company’s return to profitable operations and the timeframe of that return. While we believe it is possible, there is no 4 26 382 382 As of December 31, 2019, 2019, 2018 2017

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 2 . Commitments and Contingencies Lease commitment Our executive and administrative offices are located at 4134 1,800 January 1 June 30 July 1 not December 31, 2019 $1,200 January 1, 2020 June 30, 2020 $1,265 $7,590 six $2,548 $30,579 Litigation The Company is not not December 31, 2019. Officer Compensation On March 28, 2018, three $240,000 $100,000 $70,000 $12,000 may may Each contract provides that the Employee shall devote his entire productive time, ability, attention and energies to the business of the Company. In addition, the contracts protect the property rights of the Company, including inventions and other intellectual property, trade secrets, and proprietary information. The contracts also prohibit Employees from competing directly or indirectly with the business of the Company or its controlled subsidiaries, both during the term of the contracts, and continuing for a period of three not Effective January 28, 2019, January 28, 2019,

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	13 . Subsequent Events As stated earlier, stock compensation was accrued for the second, third, and fourth 2019 i2China not December 31, 2019. 2020. Stockholder Quarter 2nd 3rd 4th Total Shares Share Price 0.3499 0.4183 0.3043 Issued Dr. Stephen T. Chen $25,000/quarter 71,459 59,766 82,165 213,390 Bernard Cohen $ 3,000/quarter 8,575 7,172 9,860 25,607 Dr. Celee Spidel $ 1,500/quarter 4,288 2,021 - 6,309 i2China Management Group, LLC $ 6,000/quarter 17,150 14,344 19,720 51,214 Total Compensation Shares Issued 101,472 83,303 111,745 296,520 As previously stated, Dr. Stephen T. Chen, Chairman, CEO, President, and CFO, and i2China On January 1, 2020, #6.20 $216,600, 2020. January 1, 2021, AFR1 1.85%. $216,600 may $9,025 15th may $0.25 144 1933. may On January 1, 2020, #7.20 $30,000, January 1, 2021, 1 1.85%. $30,000 may may $0.25 144 1933. may On January 1, 2020, #8.20 i2China $48,000, 2020. January 1, 2021, AFR1 1.85%. $48,000 may $4,000 may $0.25 144 1933. may Following is a complete list of Convertible Notes Payable issued by the Company as of December 31, 2019, Note #. Date Payee Principal Amount Balance as of March 30, 2020 Maturity Annual Interest AFR Rate 1 Conversion Price 1 1/11/2016 Stephen T. Chen $ 144,426 $ 114,026 On Demand 0.75% $0.1680 2 3/18/2016 Stephen T. Chen $ 262,500 $ 262,500 On Demand 0.65% $0.1875 3.19 9/1/2019 Stephen T. Chen $ 72,200 $ 39,620 9/1/2020 or On Demand 1.85% $0.2500 4.19 12/1/2019 Stephen T. Chen $ 12,435 $ 12,435 12/31/2020 or On Demand 1.61% $0.2500 5.19 9/1/2019 i2China Mgt. Group LLC $ 16,000 $ 16,000 9/1/2020 or On Demand 1.85% $0.2500 6.20 1/1/2020 Stephen T. Chen $ 216,600 $ 18,050 1/1/2021 or On Demand 1.85% $0.2500 7.20 1/1/2020 Stephen T. Chen $ 30,000 - 1/2/2021 or On Demand 1.60% $0.2500 8.20 1/1/2020 i2China Mgt. Group LLC $ 48,000 $ 8,000 1/1/2021 or On Demand 1.85% $0.2500 Total Convertible Notes Payable $ 470,631 1

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Going Concern Policy [Policy Text Block]	Going Concern These financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP), on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three 1 3 ● Level 1, ● Level 2, not ● Level 3, no one Our Level 1
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company classifies investments as cash equivalents if the original maturity of an investment is three
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition In May 2014, 2014 09, August 2015, March 2016, April 2016, May 2016, December 2016 2015 14, 2016 08, 2016 10, 2016 12 2016 20, five two On January 1, 2018, 606 no no Results for reporting periods beginning after January 1, 2018 606, not 605, The Company's primary source of revenue is the sale of products within three The Medical division periodically provides medical equipment to metabolism treatment centers in Taiwan and Hong Kong. Additionally, this division provides TissueAid TM The Pharmaceutical Division is currently seeking to leverage the Company's intellectual property and core technology, low-dose oral interferon, to expand treatment of the aforementioned neoplastic, viral, and fibrotic diseases as well as other potential indications. Revenue recognized during the year ended December 31, 2019 2018
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not one no no December 31, 2019 2018. $7,320 2018.
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or market. Cost is determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Patent Expenditures ABI holds patent license agreements and maintains patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 20 No December 31, 2019. December 31, 2018, $16,000
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-lived Assets Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred. During the years ended December 31, 2019, December 31, 2018, $52,510 $32,591, not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income ( Loss ) Per Share As of December 31, 2019, 3,099,867 not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. The Company has cash balances in a single U.S. financial institution which, from time to time, could exceed the federally insured limit of $250,000. December 31, 2019, $69,634.No
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, No. 2016 02 2016 02 842 2016 02 12 2016 02 2016 02 2016 02 December 15, 2018, 2016 02 January 1, 2019. no In June 2018, 2018 07, 718 2018 07” 2018 07 718 2018 07 718 not 1 2 606 2018 07 December 15, 2018, 2018 07 January 1, 2019. 2018 07 not Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not not

Note 2 - Property, Equipment _2

Note 2 - Property, Equipment and Software, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	2019 2018 Furniture and equipment $ 94,625 $ 92,988 Automobiles 4,912 4,911 Software 8,012 8,012 107,549 105,911 Less: accumulated depreciation (102,480 ) (91,901 ) Property, equipment and software, net $ 5,069 $ 14,010

Note 3 - Patents, Net (Tables)

Note 3 - Patents, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2019 2018 Patents $ 198,655 $ 228,669 Less: accumulated amortization (52,392 ) (82,213 ) Patents, net $ 146,263 $ 146,456
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 11,957 2020 10,655 2021 10,251 2022 10,251 2023 10,251 Thereafter 92,898 Total expense $ 146,263

Note 4 - Convertible Notes Pa_2

Note 4 - Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Convertible Debt [Table Text Block]	Conversion rate Interest rate December 31 2019 December 31, 2018 Note 1 – Chen $0.1680 0.75% $ 114,026 $ 144,426 Note 2 - Chen $0.1875 0.65% 262,500 262,500 Note 3 - Chen $0.1875 0.64% - 106,430 Note 3.19 – Chen++ $0.2500 1.85% 39,620 - Note 4.19 - Chen $0.2500 1.61% 12,435 - Note 5.19 – i2China $0.2500 1.85% 16,000 - $ 444,581 $ 513,356

Note 5 - ACTS Global (Tables)

Note 5 - ACTS Global (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Issuance of Common Stock for Acquisition [Table Text Block]	Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447

Note 7 - Common Stock (Tables)

Note 7 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	Beneficiary Accrued Compensation Quarter 2 Accrued Compensation Quarter 3 Accrued Compensation Quarter 4 Total Compensation Total Shares 1 Dr. Stephen T. Chen $ 25,000 $ 25,000 $ 25,000 $ 75,000 213,390 Bernard Cohen $ 3,000 $ 3,000 $ 3,000 $ 9,000 25,607 Dr. Celee Spidel $ 1,500 $ 750 - $ 2,250 6,309 i2China Mgt., LLC $ 6,000 $ 6,000 $ 6,000 $ 18,000 51,214 Total $ 35,500 $ 34,750 $ 34,000 $ 104,250 296,520 Price Per Share $ 0.3499 $ 0.4183 $ 0.3043

Note 9 - Stock Option and Sto_2

Note 9 - Stock Option and Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Stock Plans 1 Issue Date Range Total Shares Authorized Shares Issued Shares Remaining 2008 Stock Incentive Plan 5/23/08 – 10/11/11 600,000 463,420 136,580 Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan 2 9/26/18 – 9/26/28 6,000,000 850,000 5,150,000 Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan 9/26/18 – 9/26/28 20,000,000 3,807,000 16,193,000
Share-based Payment Arrangement, Option [Member]
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Date Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance December 31, 2017 - - - - Granted 4,945,000 $ 0.38 - - Exercised - - - - Expired or Forfeited - - - - Balance December 31, 2018 4,945,000 $ 0.38 9 - Granted - - - - Exercised - - - - Forfeited 288,000 $ 0.38 - - Balance December 31, 2019 4,657,000 $ .038 8 - Total vested December 31, 2019 1,217,375 $ .038 8 -

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, 2019 December 31, 2018 Provision (benefit) at statutory rate $ (332,000 ) $ (281,000 ) Permanent differences 85,000 30,000 Change in valuation allowance 247,000 251,000 $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2019 December 31, 2018 Deferred tax assets: Net operating loss carryforward $ 5,239,000 $ 4,992,000 Deferred tax assets 5,239,000 4,992,000 Deferred tax liabilities: - - Net deferred tax assets 5,239,000 4,992,000 Valuation allowance (5,239,000 ) (4,992,000 ) $ - $ -

Note 13 - Subsequent Events (Ta

Note 13 - Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Disclosure of Accrued Share-based Compensation Arrangements [Table Text Block]	Stockholder Quarter 2nd 3rd 4th Total Shares Share Price 0.3499 0.4183 0.3043 Issued Dr. Stephen T. Chen $25,000/quarter 71,459 59,766 82,165 213,390 Bernard Cohen $ 3,000/quarter 8,575 7,172 9,860 25,607 Dr. Celee Spidel $ 1,500/quarter 4,288 2,021 - 6,309 i2China Management Group, LLC $ 6,000/quarter 17,150 14,344 19,720 51,214 Total Compensation Shares Issued 101,472 83,303 111,745 296,520
Disclosure of Convertible Notes Payable [Table Text Block]	Note #. Date Payee Principal Amount Balance as of March 30, 2020 Maturity Annual Interest AFR Rate 1 Conversion Price 1 1/11/2016 Stephen T. Chen $ 144,426 $ 114,026 On Demand 0.75% $0.1680 2 3/18/2016 Stephen T. Chen $ 262,500 $ 262,500 On Demand 0.65% $0.1875 3.19 9/1/2019 Stephen T. Chen $ 72,200 $ 39,620 9/1/2020 or On Demand 1.85% $0.2500 4.19 12/1/2019 Stephen T. Chen $ 12,435 $ 12,435 12/31/2020 or On Demand 1.61% $0.2500 5.19 9/1/2019 i2China Mgt. Group LLC $ 16,000 $ 16,000 9/1/2020 or On Demand 1.85% $0.2500 6.20 1/1/2020 Stephen T. Chen $ 216,600 $ 18,050 1/1/2021 or On Demand 1.85% $0.2500 7.20 1/1/2020 Stephen T. Chen $ 30,000 - 1/2/2021 or On Demand 1.60% $0.2500 8.20 1/1/2020 i2China Mgt. Group LLC $ 48,000 $ 8,000 1/1/2021 or On Demand 1.85% $0.2500 Total Convertible Notes Payable $ 470,631

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Number of Operating Segments	3
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 0	$ 0
Accounts Receivable, Allowance for Credit Loss, Writeoff		7,320
Write Off of Patent Costs	0	16,000
Impairment of Long-Lived Assets Held-for-use	0
Research and Development Expense, Total	$ 52,510	32,591
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	3,099,867
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 409,039	$ 1,276,654	$ 2,038,150
TAIWAN, PROVINCE OF CHINA
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 69,634
Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	15 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Asset, Useful Life	20 years

Note 2 - Property, Equipment _3

Note 2 - Property, Equipment and Software, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 10,579	$ 17,895

Note 2 - Property, Equipment _4

Note 2 - Property, Equipment and Software, Net - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, plant and equipment, gross	$ 107,549	$ 105,911
Less: accumulated depreciation	(102,480)	(91,901)
Property, equipment and software, net	5,069	14,010
Furniture and Fixtures [Member]
Property, plant and equipment, gross	94,625	92,988
Automobiles [Member]
Property, plant and equipment, gross	4,912	4,911
Software and Software Development Costs [Member]
Property, plant and equipment, gross	$ 8,012	$ 8,012

Note 3 - Patents, Net (Details

Note 3 - Patents, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Payments to Acquire Intangible Assets	$ 11,469	$ 2,369
Amortization of Intangible Assets, Total	$ 11,662	38,296
Patents [Member]
Payments to Acquire Intangible Assets		112,022
Write Off of Intangible Assets Due to Obsolete Status		96,055
Amortization of Intangible Assets, Total		$ 15,967

Note 3 - Patents, Net - Patents

Note 3 - Patents, Net - Patents (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Patents	$ 146,263	$ 146,456
Patents, net	146,263
Patents [Member]
Patents	198,655	228,669
Less: accumulated amortization	(52,392)	(82,213)
Patents, net	$ 146,263	$ 146,456

Note 3 - Patents, Net - Estimat

Note 3 - Patents, Net - Estimated Future Amortization Expense (Details)	Dec. 31, 2019USD ($)
2019	$ 11,957
2020	10,655
2021	10,251
2022	10,251
2023	10,251
Thereafter	92,898
Total expense	$ 146,263

Note 4 - Convertible Notes Pa_3

Note 4 - Convertible Notes Payable - Convertible Notes Payable, Outstanding (Details) - USD ($)		Dec. 31, 2019	Dec. 31, 2018
Convertible note payable		$ 444,581	$ 513,356
Stephen Chen [Member]
Convertible note payable		$ 428,581	513,356
Convertible Note Payable Number One [Member] | Stephen Chen [Member]
Conversion rate (in dollars per share)		$ 0.168
Interest rate	[1]	0.75%
Convertible note payable		$ 114,026	144,426
Convertible Note Payable Number Two [Member] | Stephen Chen [Member]
Conversion rate (in dollars per share)		$ 0.1875
Interest rate	[1]	0.65%
Convertible note payable		$ 262,500	262,500
Convertible Note Payable Number Three [Member] | Stephen Chen [Member]
Conversion rate (in dollars per share)		$ 0.1875
Interest rate		0.64%
Convertible note payable			106,430
Convertible Note Payable Number 3.19 [Member] | Stephen Chen [Member]
Conversion rate (in dollars per share)		$ 0.25
Interest rate	[1]	1.85%
Convertible note payable		$ 39,620
Convertible Note Payable Number 4.19 [Member] | Stephen Chen [Member]
Conversion rate (in dollars per share)		$ 0.25
Interest rate	[1]	1.61%
Convertible note payable		$ 12,435
Convertible Note Payable Number 5.19 [Member] | i2China Mgt LLC [Member]
Conversion rate (in dollars per share)		$ 0.25
Interest rate	[1]	1.85%
Convertible note payable		$ 16,000
[1]	The Short-Term Applicable Federal Rate

Note 5 - ACTS Global (Details T

Note 5 - ACTS Global (Details Textual) - shares	Jul. 12, 2018	Jul. 01, 2018	May 23, 2016
Stock Issued During Period, Shares, Acquisitions	539,447
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions		539,447
ACTS Global Healthcare, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Percentage to be Paid to Affiliate for Services Rendered			1.00%

Note 5 - ACTS Global - Voting S

Note 5 - ACTS Global - Voting Shares Issued (Details)	Jul. 12, 2018shares
Stock Issued During Period, Shares, Acquisitions	539,447
Seu Chi Kuo [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Po Ya Tseng [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Yasushi Chikagami [Member]
Stock Issued During Period, Shares, Acquisitions	53,891
Stephen/Virginia Chen Living Trust [Member]
Stock Issued During Period, Shares, Acquisitions	125,852

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - USD ($)	Jul. 12, 2018	Dec. 31, 2019	Dec. 31, 2018
Convertible Notes Payable, Total		$ 444,581	$ 513,356
Stock Issued During Period, Shares, Acquisitions	539,447
Stephen/Virginia Chen Living Trust [Member]
Stock Issued During Period, Shares, Acquisitions	125,852
Stephen Chen [Member]
Convertible Notes Payable, Total		428,581	513,356
Stephen Chen [Member] | Related Party Convertible Notes Payable [Member]
Interest Expense, Debt, Total		$ 4,094	$ 4,024

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	Feb. 15, 2020	Dec. 31, 2019	Dec. 01, 2019	Jul. 10, 2019	Apr. 26, 2019	Mar. 26, 2019	Feb. 26, 2019	Feb. 19, 2019	Jul. 12, 2018	Jul. 01, 2018	Apr. 01, 2018	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 18, 2019	Sep. 15, 2019
Common Stock, Shares Authorized		100,000,000											100,000,000	100,000,000
Common Stock, Shares Outstanding and Reserved		48,673,437											48,673,437
Common Stock, Shares, Issued, Total		40,516,351											40,516,351	39,117,524
Common Stock, Shares Subscribed but Unissued		2,350,949											2,350,949
Proceeds from Issuance of Private Placement													$ 125,048	$ 401,250
Deferred Compensation Arrangement with Individual, Shares Issued														451,480
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued														$ 116,250
Debt Conversion, Original Debt, Amount													100,000	178,125
Stock Issued During Period, Shares, Acquisitions									539,447
Stock Issued During Period, Value, New Issues													$ 130,000	$ 1,122,285
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														4,945,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		1,217,375											1,217,375
Dividends, Total													$ 0
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions										539,447
Consultants [Member]
Shares Issued, Price Per Share					$ 0.3711		$ 0.25
Stock Issued During Period, Shares, Issued for Services							24,000
Stock Issued During Period, Value, Issued for Services							$ 6,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					16,170
Share-based Payment Arrangement, Noncash Expense, Total												$ 6,000
Stephen Chen [Member]
Deferred Compensation Arrangement with Individual, Shares Issued							100,000
Debt Conversion, Original Debt, Amount											$ 178,125
Debt Conversion, Converted Instrument, Shares Issued											950,000
Shares Issued, Price Per Share					$ 0.3711						$ 0.1875
Deferred Compensation Arrangement with Individual, Exercise Price							$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					67,377
Share-based Payment Arrangement, Noncash Expense, Total												25,000
Bernard Cohen [Member]
Deferred Compensation Arrangement with Individual, Shares Issued							12,000
Shares Issued, Price Per Share					$ 0.3711
Deferred Compensation Arrangement with Individual, Exercise Price							$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					8,085
Share-based Payment Arrangement, Noncash Expense, Total												3,000
Dr. Stephen T. Chen, and Bernard Cohen [Member]
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued							$ 28,000
Finders [Member]
Shares Issued, Price Per Share						$ 0.25
Stock Issued During Period, Shares, Issued for Services						115,000
Stock Issued During Period, Value, Issued for Services						$ 28,750
Dr. Celee Spidel [Member]
Shares Issued, Price Per Share					$ 0.3711
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					4,043
Share-based Payment Arrangement, Noncash Expense, Total												$ 1,500
Chief Executive Officer [Member] | Conversion of Promissory Note to ABI Common Voting Shares [Member]
Debt Conversion, Original Debt, Amount				$ 68,930
Debt Conversion, Converted Instrument, Shares Issued				371,200
Debt Conversion, Original Debt, Accrued Interest, Amount				$ 670
Debt Instrument, Convertible, Conversion Price				$ 0.1875
Chief Executive Officer [Member] | Conversion of Promissory Note Dated January 11, 2016 into Company Shares [Member]
Debt Conversion, Original Debt, Amount				$ 30,400
Debt Conversion, Converted Instrument, Shares Issued				180,952
Debt Instrument, Convertible, Conversion Price				$ 0.1681
Warrant [Member]
Common Stock, Capital Shares Reserved for Future Issuance		452,617											452,617
Options [Member]
Common Stock, Capital Shares Reserved for Future Issuance		4,657,000											4,657,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross													4,657,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		1,217,375											1,217,375
Officer [Member]
Common Stock, Capital Shares Reserved for Future Issuance		238,997											238,997
Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance		6,309											6,309
Consultants [Member]
Common Stock, Capital Shares Reserved for Future Issuance		51,214											51,214
Private Placement [Member]
Common Stock, Capital Shares Reserved for Future Issuance		400,000											400,000
First Issuance to Investors [Member]
Stock Issued During Period, Shares, New Issues														3,740,973
Proceeds from Issuance of Private Placement														$ 721,035
Second Issuance to Investors [Member]
Stock Issued During Period, Shares, New Issues														1,700,000
Proceeds from Issuance of Private Placement														$ 401,250
Private Placement 2016-3 [Member]
Stock Issued During Period, Shares, New Issues								200,000
Shares Issued, Price Per Share								$ 0.25
Stock Issued During Period, Value, New Issues								$ 50,000
Private Placement 2016-2 [Member]
Stock Issued During Period, Shares, New Issues			300,000
Shares Issued, Price Per Share			$ 0.1875
Stock Issued During Period, Value, New Issues			$ 56,250
Private Placement 2019-01 [Member] | Maximum [Member]
Common Stock, Shares Subscribed but Unissued																24,000,000
Common Stock, Value, Subscriptions																$ 6,000,000
Private Placement 2019-02 [Member]
Proceeds from Issuance of Private Placement		$ 100,000
Common Stock, Value, Subscriptions															$ 3,000,000
Sale of Stock, Price Per Share															$ 0.25
Private Placement 2019-02 [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	400,000
Sale of Stock, Price Per Share	$ 0.25
Private Placement 2019-02 [Member] | Maximum [Member]
Common Stock, Shares Subscribed but Unissued															12,000,000

Note 7 - Common Stock - Accrued

Note 7 - Common Stock - Accrued Stock Compensation (Details) - USD ($)		Feb. 26, 2019	Dec. 31, 2019
Accrued Compensation			$ 104,250
Total Shares (in shares)	[1]		296,520
i2China Mgt LLC [Member]
Accrued Compensation			$ 18,000
Total Shares (in shares)	[1]		51,214
Stephen Chen [Member]
Accrued Compensation			$ 75,000
Total Shares (in shares)	[1]		213,390
Price Per Share (in dollars per share)		$ 0.25
Bernard Cohen [Member]
Accrued Compensation			$ 9,000
Total Shares (in shares)	[1]		25,607
Price Per Share (in dollars per share)		$ 0.25
Dr. Celee Spidel [Member]
Accrued Compensation			$ 2,250
Total Shares (in shares)	[1]		6,309
Share-based Compensation, Accrued Compensation Quarter Two [Member]
Accrued Compensation			$ 35,500
Total Shares (in shares)			101,472
Price Per Share (in dollars per share)			$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Two [Member] | i2China Mgt LLC [Member]
Accrued Compensation			$ 6,000
Price Per Share (in dollars per share)			$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Stephen Chen [Member]
Accrued Compensation			$ 25,000
Total Shares (in shares)			71,459
Price Per Share (in dollars per share)			$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Bernard Cohen [Member]
Accrued Compensation			$ 3,000
Total Shares (in shares)			8,575
Price Per Share (in dollars per share)			$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Dr. Celee Spidel [Member]
Accrued Compensation			$ 1,500
Total Shares (in shares)			4,288
Price Per Share (in dollars per share)			$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Three [Member]
Accrued Compensation			$ 34,750
Total Shares (in shares)			83,303
Price Per Share (in dollars per share)			$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Three [Member] | i2China Mgt LLC [Member]
Accrued Compensation			$ 6,000
Price Per Share (in dollars per share)			$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Stephen Chen [Member]
Accrued Compensation			$ 25,000
Total Shares (in shares)			59,766
Price Per Share (in dollars per share)			$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Bernard Cohen [Member]
Accrued Compensation			$ 3,000
Total Shares (in shares)			7,172
Price Per Share (in dollars per share)			$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Dr. Celee Spidel [Member]
Accrued Compensation			$ 750
Total Shares (in shares)			2,021
Price Per Share (in dollars per share)			$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Four [Member]
Accrued Compensation			$ 34,000
Total Shares (in shares)			111,745
Price Per Share (in dollars per share)			$ 0.3043
Share-based Compensation, Accrued Compensation Quarter Four [Member] | i2China Mgt LLC [Member]
Accrued Compensation			$ 6,000
Price Per Share (in dollars per share)			$ 0.3043
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Stephen Chen [Member]
Accrued Compensation			$ 25,000
Total Shares (in shares)			82,165
Price Per Share (in dollars per share)			$ 0.3043
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Bernard Cohen [Member]
Accrued Compensation			$ 3,000
Total Shares (in shares)			9,860
Price Per Share (in dollars per share)			$ 0.3043
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Dr. Celee Spidel [Member]
Accrued Compensation
Total Shares (in shares)
Price Per Share (in dollars per share)			$ 0.3043
[1]	Total number of shares reserved for the compensation accrued in 2019 and total number of shares issued on February 15, 2020 for 2019 stock compensation.

Note 8 - Preferred Stock (Detai

Note 8 - Preferred Stock (Details Textual) - shares	Mar. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized		10,000,000	10,000,000
Preferred Stock, Shares Outstanding, Ending Balance		0	0
Subsequent Event [Member]
Preferred Stock, Shares Outstanding, Ending Balance	0

Note 9 - Stock Option and Sto_3

Note 9 - Stock Option and Stock Plans (Details Textual) - USD ($)	Sep. 26, 2018	Dec. 31, 2019		Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		4,657,000	[1]	4,945,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		276.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Discount Rate		2.96%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 1,308,932
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		3 years 273 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0		0
Qualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000
Stock Option Price, Percent	100.00%
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Qualified Options [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Stock Option, Exercise Price		$ 0.418
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		500,000
Qualified Options [Member] | If Option Grantee Owns or Controls Over Ten Percent of Outstanding Stock [Member]
Stock Option Price, Percent	110.00%
Stock Option, Exercise Price	$ 0.418
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Qualified Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Payment Arrangement, Tranche One [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Four [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Nonqualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	20,000,000
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Nonqualified Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this option-holder would be $0.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 9 - Stock Option and Sto_4

Note 9 - Stock Option and Stock Plans - Stock Option Plan Summary (Details)	12 Months Ended
	Dec. 31, 2019shares	[1]
2008 Stock Incentive Plan [Member]
Total Shares Authorized (in shares)	600,000
Shares Issued (in shares)	463,420
Shares Remaining (in shares)	136,580
2018 Employee Stock Option Plan [Member]
Total Shares Authorized (in shares)	6,000,000	[2]
Shares Issued (in shares)	850,000	[2]
Shares Remaining (in shares)	5,150,000	[2]
2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan [Member]
Total Shares Authorized (in shares)	20,000,000
Shares Issued (in shares)	3,807,000
Shares Remaining (in shares)	16,193,000
[1]	The Board of Directors has approved all stock, stock option and stock warrant issuances.
[2]	On September 26, 2019, all Qualified Options became non-qualified options since the 2018-ESOP was not ratified by the stockholders.

Note 9 - Stock Option and Sto_5

Note 9 - Stock Option and Stock Plans - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018	Dec. 31, 2017
Number of Options, Outstanding (in shares)	4,945,000
Weighted Average Exercise Price, Outstanding (in dollars per share)	$ 0.38
Weighted Average Remaining Contractual Term, Outstanding (Year)	8 years		9 years
Aggregate Intrinsic Value, Outstanding
Number of Options, Granted (in shares)			4,945,000
Weighted Average Exercise Price, Granted (in dollars per share)			$ 0.38
Weighted Average Remaining Contractual Term, Granted (Year)
Number of Options, Exercised (in shares)	0		0
Number of Options, Expired or Forfeited (in shares)
Weighted Average Exercise Price, Expired or Forfeited (in dollars per share)
Number of Options, Forfeited (in shares)	288,000
Weighted Average Exercise Price, Forfeited (in dollars per share)	$ 0.38
Number of Options, Outstanding (in shares)	4,657,000	[1]	4,945,000
Weighted Average Exercise Price, Outstanding (in dollars per share)	$ 0.038		$ 0.38
Number of Options, Vested (in shares)	1,217,375
Weighted Average Exercise Price, Vested (in dollars per share)	$ 0.038
Weighted Average Remaining Contractual Term, Vested (Year)	8 years
Aggregate Intrinsic Value, Vested
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this option-holder would be $0.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 10 - Warrants (Details Tex

Note 10 - Warrants (Details Textual)	12 Months Ended
	Dec. 31, 2019yrshares	Dec. 31, 2018shares	Apr. 15, 2018USD ($)$ / sharesshares
Class Of Warrant Or Right, Exercised	0	0
Warrants Issued to Consultants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			452,617
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.27
Warrants and Rights Outstanding | $			$ 75,967
Warrants and Rights Outstanding, Term			2 years
Warrants Issued to Consultants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	2.07
Warrants Issued to Consultants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	2
Warrants Issued to Consultants [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0239

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2019USD ($)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Operating Loss Carryforwards, Total	$ 24,948,000
Open Tax Year	2019 2018 2017

Note 11 - Income Taxes - Income

Note 11 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Provision (benefit) at statutory rate	$ (332,000)	$ (281,000)
Permanent differences	85,000	30,000
Change in valuation allowance	247,000	251,000

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforward	$ 5,239,000	$ 4,992,000
Deferred tax assets	5,239,000	4,992,000
Deferred tax liabilities:
Net deferred tax assets	5,239,000	4,992,000
Valuation allowance	(5,239,000)	(4,992,000)

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual)	Mar. 28, 2018USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)ft²
Chief Executive Officer [Member]
Officer Compensation, Annual Compensation, Cash	$ 240,000
Officer Compensation, Annual Compensation, Share Value	100,000
Chief Financial Officer [Member]
Officer Compensation, Annual Compensation, Cash	70,000
Officer Compensation, Annual Compensation, Share Value	$ 12,000
Forecast [Member]
Operating Leases Rent Expense Monthly Amount		$ 1,265
Operating Lease, Expense		$ 7,590
Forecast [Member] | TAIWAN, PROVINCE OF CHINA
Operating Leases Rent Expense Monthly Amount			$ 2,548
Operating Lease, Expense			$ 30,579
Executive and Administrative Offices [Member]
Area of Real Estate Property | ft²				1,800
Operating Leases Rent Expense Monthly Amount				$ 1,200

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)		Mar. 30, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
Convertible Notes Payable, Total				$ 444,581	$ 513,356
Subsequent Event [Member]
Convertible Notes Payable, Total		$ 470,631
Convertible Note Payable Number 8.20 [Member] | Subsequent Event [Member] | i2China Mgt LLC [Member]
Convertible Notes Payable, Total		8,000	$ 48,000
Debt Instrument, Interest Rate, Stated Percentage	[1]		1.85%
Convertible Notes Payable, Monthly Advance Payment, Maximum			$ 4,000
Debt Instrument, Convertible, Conversion Price			$ 0.25
Stephen Chen [Member]
Convertible Notes Payable, Total				$ 428,581	$ 513,356
Stephen Chen [Member] | Convertible Note Payable Number 6.20 [Member] | Subsequent Event [Member]
Convertible Notes Payable, Total		18,050	$ 216,600
Debt Instrument, Interest Rate, Stated Percentage	[1]		1.85%
Convertible Notes Payable, Monthly Advance Payment, Maximum			$ 9,025
Debt Instrument, Convertible, Conversion Price			$ 0.25
Stephen Chen [Member] | Convertible Note Payable Number 7.20 [Member] | Subsequent Event [Member]
Convertible Notes Payable, Total			$ 30,000
Debt Instrument, Interest Rate, Stated Percentage			1.85%
Debt Instrument, Convertible, Conversion Price			$ 0.25
[1]	The Short-Term Applicable Federal Rate

Note 13 - Subsequent Events - A

Note 13 - Subsequent Events - Accrued Stock Compensation (Details)	Dec. 31, 2019shares
Total Shares Issued (in shares)	296,520	[1]
Stephen Chen [Member]
Total Shares Issued (in shares)	213,390	[1]
Bernard Cohen [Member]
Total Shares Issued (in shares)	25,607	[1]
Dr. Celee Spidel [Member]
Total Shares Issued (in shares)	6,309	[1]
i2China Mgt LLC [Member]
Total Shares Issued (in shares)	51,214
Share-based Compensation, Accrued Compensation Quarter Two [Member]
Total Shares Issued (in shares)	101,472
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Stephen Chen [Member]
Total Shares Issued (in shares)	71,459
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Bernard Cohen [Member]
Total Shares Issued (in shares)	8,575
Share-based Compensation, Accrued Compensation Quarter Two [Member] | Dr. Celee Spidel [Member]
Total Shares Issued (in shares)	4,288
Share-based Compensation, Accrued Compensation Quarter Two [Member] | i2China Mgt LLC [Member]
Total Shares Issued (in shares)	17,150
Share-based Compensation, Accrued Compensation Quarter Three [Member]
Total Shares Issued (in shares)	83,303
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Stephen Chen [Member]
Total Shares Issued (in shares)	59,766
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Bernard Cohen [Member]
Total Shares Issued (in shares)	7,172
Share-based Compensation, Accrued Compensation Quarter Three [Member] | Dr. Celee Spidel [Member]
Total Shares Issued (in shares)	2,021
Share-based Compensation, Accrued Compensation Quarter Three [Member] | i2China Mgt LLC [Member]
Total Shares Issued (in shares)	14,344
Share-based Compensation, Accrued Compensation Quarter Four [Member]
Total Shares Issued (in shares)	111,745
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Stephen Chen [Member]
Total Shares Issued (in shares)	82,165
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Bernard Cohen [Member]
Total Shares Issued (in shares)	9,860
Share-based Compensation, Accrued Compensation Quarter Four [Member] | Dr. Celee Spidel [Member]
Total Shares Issued (in shares)
Share-based Compensation, Accrued Compensation Quarter Four [Member] | i2China Mgt LLC [Member]
Total Shares Issued (in shares)	19,720
[1]	Total number of shares reserved for the compensation accrued in 2019 and total number of shares issued on February 15, 2020 for 2019 stock compensation.

Note 13 - Subsequent Events -_2

Note 13 - Subsequent Events - Accrued Stock Compensation (Details) (Parentheticals) - USD ($)	Feb. 26, 2019	Dec. 31, 2019
Share-based Compensation, Accrued Compensation Quarter Two [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3499
Share-based Compensation, Accrued Compensation Quarter Two [Member] | i2China Mgt LLC [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3499
Stock Compensation Per Quarter		$ 6,000
Share-based Compensation, Accrued Compensation Quarter Three [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.4183
Share-based Compensation, Accrued Compensation Quarter Three [Member] | i2China Mgt LLC [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.4183
Stock Compensation Per Quarter		$ 6,000
Share-based Compensation, Accrued Compensation Quarter Four [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3043
Share-based Compensation, Accrued Compensation Quarter Four [Member] | i2China Mgt LLC [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3043
Stock Compensation Per Quarter		$ 6,000
Stephen Chen [Member]
Deferred Compensation Arrangement with Individual, Exercise Price	$ 0.25
Stephen Chen [Member] | Share-based Compensation, Accrued Compensation Quarter Two [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3499
Stock Compensation Per Quarter		$ 25,000
Stephen Chen [Member] | Share-based Compensation, Accrued Compensation Quarter Three [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.4183
Stock Compensation Per Quarter		$ 25,000
Stephen Chen [Member] | Share-based Compensation, Accrued Compensation Quarter Four [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3043
Stock Compensation Per Quarter		$ 25,000
Bernard Cohen [Member]
Deferred Compensation Arrangement with Individual, Exercise Price	$ 0.25
Bernard Cohen [Member] | Share-based Compensation, Accrued Compensation Quarter Two [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3499
Stock Compensation Per Quarter		$ 3,000
Bernard Cohen [Member] | Share-based Compensation, Accrued Compensation Quarter Three [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.4183
Stock Compensation Per Quarter		$ 3,000
Bernard Cohen [Member] | Share-based Compensation, Accrued Compensation Quarter Four [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3043
Stock Compensation Per Quarter		$ 3,000
Dr. Celee Spidel [Member] | Share-based Compensation, Accrued Compensation Quarter Two [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3499
Stock Compensation Per Quarter		$ 1,500
Dr. Celee Spidel [Member] | Share-based Compensation, Accrued Compensation Quarter Three [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.4183
Stock Compensation Per Quarter		$ 1,500
Dr. Celee Spidel [Member] | Share-based Compensation, Accrued Compensation Quarter Four [Member]
Deferred Compensation Arrangement with Individual, Exercise Price		$ 0.3043
Stock Compensation Per Quarter		$ 1,500

Note 13 - Subsequent Events - C

Note 13 - Subsequent Events - Convertible Notes Payable (Details) - USD ($)		Mar. 30, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
Convertible note payable				$ 444,581	$ 513,356
Subsequent Event [Member]
Convertible note payable		$ 470,631
Convertible Note Payable Number 5.19 [Member] | i2China Mgt LLC [Member]
Principal Amount				16,000
Convertible note payable				$ 16,000
Interest rate	[1]			1.85%
Conversion rate (in dollars per share)				$ 0.25
Convertible Note Payable Number 5.19 [Member] | Subsequent Event [Member] | i2China Mgt LLC [Member]
Convertible note payable		16,000
Convertible Note Payable Number 8.20 [Member] | Subsequent Event [Member] | i2China Mgt LLC [Member]
Principal Amount			$ 48,000
Convertible note payable		8,000	$ 48,000
Interest rate	[1]		1.85%
Conversion rate (in dollars per share)			$ 0.25
Stephen Chen [Member]
Convertible note payable				$ 428,581	513,356
Stephen Chen [Member] | Convertible Note Payable Number One [Member]
Principal Amount				144,426
Convertible note payable				$ 114,026	144,426
Interest rate	[1]			0.75%
Conversion rate (in dollars per share)				$ 0.168
Stephen Chen [Member] | Convertible Note Payable Number One [Member] | Subsequent Event [Member]
Convertible note payable		114,026
Stephen Chen [Member] | Convertible Note Payable Number Two [Member]
Principal Amount				$ 262,500
Convertible note payable				$ 262,500	262,500
Interest rate	[1]			0.65%
Conversion rate (in dollars per share)				$ 0.1875
Stephen Chen [Member] | Convertible Note Payable Number Two [Member] | Subsequent Event [Member]
Convertible note payable		262,500
Stephen Chen [Member] | Convertible Note Payable Number 3.19 [Member]
Principal Amount				$ 72,200
Convertible note payable				$ 39,620
Interest rate	[1]			1.85%
Conversion rate (in dollars per share)				$ 0.25
Stephen Chen [Member] | Convertible Note Payable Number 3.19 [Member] | Subsequent Event [Member]
Convertible note payable		39,620
Stephen Chen [Member] | Convertible Note Payable Number 4.19 [Member]
Principal Amount				$ 12,435
Convertible note payable				$ 12,435
Interest rate	[1]			1.61%
Conversion rate (in dollars per share)				$ 0.25
Stephen Chen [Member] | Convertible Note Payable Number 4.19 [Member] | Subsequent Event [Member]
Convertible note payable		12,435
Stephen Chen [Member] | Convertible Note Payable Number 6.20 [Member] | Subsequent Event [Member]
Principal Amount			$ 216,600
Convertible note payable		18,050	$ 216,600
Interest rate	[1]		1.85%
Conversion rate (in dollars per share)			$ 0.25
Stephen Chen [Member] | Convertible Note Payable Number 7.20 [Member] | Subsequent Event [Member]
Principal Amount			$ 30,000
Convertible note payable			$ 30,000
Interest rate			1.85%
Conversion rate (in dollars per share)			$ 0.25
[1]	The Short-Term Applicable Federal Rate